Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint Announces Licensing of Additional Heart Analysis Technology from the University of Washington

V.VPT

SEATTLE, WASHINGTON--(Marketwired - Jan. 21, 2016) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) is pleased to announce that is has licensed the knowledge-based reconstruction (KBR) technology for the left atrium and right atrium of the heart.

"This new technology will allow the Company to offer accurate and rapid analysis of all 4 chambers of the heart," stated Dr. George Adams, CEO of Ventripoint, "Cardiologists worldwide need this information to understand what is wrong with the whole heart."

The Company had previously licensed the KBR technology for the right ventricle and left ventricle from the University of Washington and has now amended that license to include the right and left atria. The technology includes starting anatomical models of the heart chambers, which allows for the rapid construction of the catalogues (heart databases) used in KBR. The Company is now working to complete the catalogues and test them to file a submission to the regulatory agencies in Canada, Europe and the United States for marketing approvals in the next few months.

Forward Looking Statement:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

George Adams, President and CEO
(206) 910-9125
gadams@ventripoint.ca